Nicotinamide, a glucose-6-phosphate dehydrogenase non-competitive mixed inhibitor, modifies redox balance and lipid accumulation in 3T3-L1 cells

• Published in: Life sciences (1973) 2013-12, Vol.93 (25-26), p.975-985
• Main Authors: Torres-Ramírez, Nayeli, Baiza-Gutman, Luis Arturo, García-Macedo, Rebeca, Ortega-Camarillo, Clara, Contreras-Ramos, Alejandra, Medina-Navarro, Rafael, Cruz, Miguel, Ibáñez-Hernández, Miguel Ángel, Díaz-Flores, Margarita
• Format: Article
• Language: English
• Subjects: 3T3-L1 Cells - drug effects; Adipocyte; adipocytes; Adipogenesis; Animals; apoptosis; Apoptosis - drug effects; Cell Differentiation - drug effects; Cell Survival - drug effects; cell viability; cultured cells; dietary carbohydrate; energy; Enzyme Inhibitors - pharmacology; Fatty Acids - metabolism; glucose; Glucose - metabolism; glucose-6-phosphate 1-dehydrogenase; Glucose-6-phosphate dehydrogenase; Glucosephosphate Dehydrogenase - antagonists & inhibitors; Glucosephosphate Dehydrogenase - genetics; Glucosephosphate Dehydrogenase - metabolism; Glycerol - metabolism; isocitrate dehydrogenase; Lipid Metabolism - drug effects; Lipids; lipolysis; malic enzyme; messenger RNA; Mice; NAD (coenzyme); NAD(P); NAD(P)H; NADP (coenzyme); NADP - metabolism; Niacinamide - pharmacology; Nicotinamide; Oxidation-Reduction; Oxidative stress; reactive oxygen species; Reactive Oxygen Species - metabolism; Reductive power
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2013.10.023

Excessive energy uptake of dietary carbohydrates results in their storage as fat and requires glucose-6-phosphate dehydrogenase (G6PD)-mediated NADPH production. We sought to assess whether the nicotinamide-induced reduction of G6PD activity might modulate redox balance and lipid accumulation in 3T3-L1 cells. 3T3-L1 preadipocytes (days 4 and 6 of differentiation) and adipocytes were cultured in the presence of 5 or 25mM glucose. The cells cultured in 25mM glucose were supplemented with nicotinamide (5–15mM). Next, we evaluated the following parameters: cell viability, apoptosis, lipid accumulation, lipolysis, reducing power, reactive oxygen species (ROS), NAD(P)H and NAD(P)+, isocitrate dehydrogenase (IDP), malic enzyme and G6PD, as well as the protein and mRNA levels of G6PD. We also analysed the kinetics of the nicotinamide-induced inhibition of G6PD. G6PD mRNA levels increased at day 4 of adipocyte differentiation, whereas G6PD activity progressively increased at days 4 and 6 of differentiation and was reduced in adipocytes. Concomitantly, ROS, reducing power and lipid accumulation increased gradually as the preadipocytes matured into adipocytes. High glucose increased the activity of G6PD, which coincided with an increase in ROS, reducing power and lipid accumulation. All of these changes are prevented by nicotinamide, with the exception of lipid accumulation in adipocytes. Nicotinamide increased IDP activity without affecting NADPH levels. Lastly, nicotinamide inhibited G6PD in a non-competitive mixed way. Nicotinamide modulates G6PD via a non-competitive mixed inhibition and decreases high glucose-dependent oxidative stress and lipid accumulation. Nicotinamide maintains NADPH levels by increasing the activity of IDP.